Dr. Borghaei on 2-Year Findings With Nivolumab Vs Docetaxel in NSCLC

(2:22)

Dr. Borghaei on Emerging Biomarkers in NSCLC

(2:2)

Dr. Hossein Borghaei shares what he finds most exciting from #ASCO18

(3:47)

Dr. Borghaei Discusses the PACIFIC Trial in Lung Cancer

(1:54)

Dr. Borghaei on the FDA Approval of Nivolumab in Small Cell Lung Cancer

(1:33)

Dr. Borghaei on Immune-Related Adverse Events in Lung Cancer

(1:2)

Hossein Borghaei, DO

(2:26)

Dr. Borghaei on Reporting Immunotherapy-Related AEs in Lung Cancer

(1:41)

Dr. Borghaei on Anticipated Trials Evaluating Immunotherapy in NSCLC

(1:37)

Replay of the Live Conversation with Dr. Barbara Natterson Horowitz

(1:5:46)

010: Dr. Brannon Wheeler on UAP, Non-Human Intelligences, and the History of Religion

(1:43:58)

Neurosurgery written board crash course - cerebellum part 2

(8:16)

Epigenetics Explained

(3:42)

Neurosurgery written board crash course - cerebellum part 1

(14:16)

Revolutionizing Healthcare - Speciality Spotlight: AI in Oncology

(58:45)

Axiom Crossroads: Reimagining Clinical Trials

(39:37)

IASLC Webinar: World Conference on Lung Cancer 2020 Highlights

(59:17)

Death to Life with Immunotherapy: Stefanie's Story

(12:54)

Dr. Borghaei on the CheckMate-227 Trial in NSCLC

(2:17)

Copy of Dr. Borghaei on Molecular Profiling in Lung Cancer

(24)

Dr. Borghaei on the Search for Biomarkers in Lung Cancer

(1:36)

Dr. Borghaei on Immunotherapy versus Chemotherapy and Immunotherapy in NSCLC

(1:11)

Dr. Borghaei on the Clinical Utility of PD-L1 in Advanced NSCLC

(1:29)

Dr. Borghaei on Molecular Profiling in Lung Cancer

(1:35)

Dr. Borghaei on the Management of Immune-Related Side Effects in Lung Cancer

(2:5)

Dr. Borghaei on the Current Landscape of Immunotherapy in NSCLC

(2:3)

Dr. Hossein Borghaei: Immunotherapy \u0026 Small Cell Lung Cancer

(50:45)

Copy of Dr. Borghaei on the Current Landscape of Immunotherapy in NSCLC

(18)

Dr. Borghaei on Second-Line Therapy in SCLC

(2:8)